50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Conference

related documents

• A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.  Conference Paper
• A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas.  Conference Paper
• A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.  Conference Paper
• A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers.  Conference Paper
• A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21).  Conference Paper
• A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial.  Conference Paper
• A targeted intervention to improve awareness to molecular testing in NSCLC.  Conference Paper
• Adjuvant radiation, androgen deprivation, and docetaxel for high-risk prostate cancer post-prostatectomy: Results of RTOG 0621.  Conference Paper
• Androgen pathway manipulation and outcome in elderly men with non-small cell lung cancer: A population-based study from Ontario, Canada.  Conference Paper
• Assessment of a dyspnea clinic for patients with thoracic malignancies  Conference Paper
• Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study.  Conference Paper
• Correlation between phase 2 clinical trial design and subsequent phase 3 outcome.  Conference Paper
• Do patients with small cell lung cancer (SCLC) who have chemotherapy initiated during a hospital admission benefit from therapy?  Conference Paper
• Does routine symptom screening with the Edmonton Symptom Assessment System (ESAS) decrease emergency department visits in breast cancer patients undergoing adjuvant chemotherapy?  Conference Paper
• Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.  Conference Paper
• Evaluation of the adjuvant radiation treatment-effect heterogeneity using genomic signature for locoregional relapse and long-term outcome.  Conference Paper
• Experimental fertility preservation (FP) interventions in prepubertal (PP) boys with cancer: A report on preferences of teenage cancer survivors, parents, and providers.  Conference Paper
• External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC).  Conference Paper
• Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.  Conference Paper
• First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L), or their combination T plus L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).  Conference Paper
• First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.  Conference Paper
• Impact of health care professional interventions on completion of therapy in patients receiving high-dose interferon-alfa 2b adjuvant therapy for high-risk melanoma.  Conference Paper
• Interobserver variation in predicting fracture risk in patients with long bone metastatic lesions.  Conference Paper
• NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.  Conference Paper
• Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.  Conference Paper
• Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).  Conference Paper
• Outcome of childhood T-cell acute lymphoblastic leukemia (T-ALL): Results from DFCI protocol 05-001.  Conference Paper
• Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.  Conference Paper
• Pharmacokinetic analysis of tamoxifen metabolites in premenopausal women with early breast cancer: A substudy of NCIC CTG MA.12 randomized clinical trial.  Conference Paper
• Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.  Conference Paper
• Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.  Conference Paper
• Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium.  Conference Paper
• Population-based evaluation of 21-gene assay in treatment decision making for early breast cancer in Ontario.  Conference Paper
• Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity.  Conference Paper
• Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.  Conference Paper
• Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC).  Conference Paper
• Prognostic factors in hemangioendotheliomas (HE): Analysis based on the Surveillance, Epidemiology, and End Results (SEER) program.  Conference Paper
• Prognostic potential of thyroid receptor TRα2 in breast cancer.  Conference Paper
• Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).  Conference Paper
• Reasons for delay in time to initiation of adjuvant chemotherapy for colon cancer: A multi-institution study.  Conference Paper
• Results from an interdisciplinary palliative rehabiliation program for patients living with advanced cancer.  Conference Paper
• The use of health-related quality of life outcomes in oncology practice: An international study.  Conference Paper
• Using Magee equations to predict Oncotype DX recurrence scores: A potential cost and time saving strategy?  Conference Paper
• Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl).  Conference Paper